Balkrishna Acharya, Sinha Sandeep, Karumuri Shadrak, Srivastava Jyotish, Haldar Swati, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, India.
Department of Allied and Applied Sciences, University of Patanjali, Haridwar, India.
Front Pharmacol. 2022 May 4;13:883475. doi: 10.3389/fphar.2022.883475. eCollection 2022.
The inflammatory cartilaginous degeneration of the articular joints, mostly those of knee, hips and hands, is osteoarthritis (OA). The available treatment strategies for osteoarthritis are designed for pain relief, molecular targeting, cartilage regeneration and surgical intervention. However, meta-analysis of clinical trials has shown these strategies to be sub-optimal, thereby, eliciting a need for investigating alternative options. The herbo-mineral formulation, Peedanil Gold (PN-G) has been used against joint pains and inflammation. In the current study, anti-osteoarthritic effects of PN-G were investigated in rat model of OA, induced by intra-articular injection of monosodium-iodoacetate. PN-G treatment improved the clinical and Kellgren & Lawrence scores; and rescued the osteoarthritic rats from hyperalgesia and allodynia. Besides, PN-G treatment ameliorated joint inflammation and abrogated osteoarthritic pathology through effective cartilage regeneration, measured radiologically and histopathologically. PN-G also reduced the levels of interleukin-6 (IL-6) and interleukin-1 beta (IL-1β), in a dose dependent manner, in inflamed human macrophagic THP-1 cells, thereby, reaffirming its anti-inflammatory property at cytosafe concentrations. Ultra High performance liquid chromatography (UHPLC) revealed the presence of several analgesic and anti-inflammatory phytocompounds, like ellagic acid, guggulsterone E, guggulsterone Z, 5-(hydroxymethyl) furfural, corilagin, cinnamic acid, ferulic acid, gallic acid and protocatechuic acid in PN-G. In conclusion, this study has succinctly demonstrated that PN-G is capable of relieving the clinical symptoms of osteoarthritis, which is measurable through the established osteoarthritic serum biomarker, Cartilage Oligomeric Matrix Protein (COMP).
关节的炎性软骨退变,主要发生在膝关节、髋关节和手部关节,即骨关节炎(OA)。现有的骨关节炎治疗策略旨在缓解疼痛、分子靶向治疗、软骨再生和手术干预。然而,对临床试验的荟萃分析表明这些策略并非最佳选择,因此,需要研究其他替代方案。草药-矿物质配方Peedanil Gold(PN-G)已被用于治疗关节疼痛和炎症。在本研究中,通过关节内注射碘乙酸钠诱导大鼠骨关节炎模型,研究了PN-G的抗骨关节炎作用。PN-G治疗改善了临床和凯尔格伦&劳伦斯评分;并使骨关节炎大鼠免于痛觉过敏和异常性疼痛。此外,PN-G治疗减轻了关节炎症,并通过放射学和组织病理学测量的有效软骨再生消除了骨关节炎病理。PN-G还以剂量依赖性方式降低了炎症人巨噬细胞THP-1细胞中白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)的水平,从而在细胞安全浓度下再次证实了其抗炎特性。超高效液相色谱(UHPLC)显示PN-G中存在几种镇痛和抗炎植物化合物,如鞣花酸、古芸香烯E、古芸香烯Z、5-(羟甲基)糠醛、柯里拉京、肉桂酸、阿魏酸、没食子酸和原儿茶酸。总之,本研究简要证明了PN-G能够缓解骨关节炎的临床症状,这可通过已确立的骨关节炎血清生物标志物软骨寡聚基质蛋白(COMP)来衡量。